The company received funding from the Chief Scientist and Trendlines.
The Office of the Chief Scientist, Eli Opper, and Trendlines International Ltd. have jointly invested NIS 2 million in Misgav Venture Accelerator incubator company RealView Medical Ltd. The company is developing an implantable device for long-term monitoring of bladder cancer.
The Misgav incubator is owned by the Trendlines Group.
Muscle invasive transitional cell carcinoma or bladder cancer is characterized by a very high recurrence rate of 70% within the first two years following detection. Early detection increases the chances of preventing a metastastic bladder from penetrating the muscle layer. Patients who have been diagnosed with the cancer are required to undergo an intensive process of uncomfortable and life-threatening monitoring and invasive examinations. The RealView monitoring system offers a simple way of closely yet comfortably monitoring patients.
The CEO of RealView is former Given Imaging VP Haim Akerman.
Published by Globes [online], Israel business news - www.globes-online.com - on November 18, 2008
© Copyright of Globes Publisher Itonut (1983) Ltd. 2008